Download PDF
Dtsch Med Wochenschr 2002; 127(31/32): 1645-1647
DOI: 10.1055/s-2002-33204
Der Arzneistoff
© Georg Thieme Verlag Stuttgart · New York

Niedermolekulare Heparine

Low molecular weight heparinsF. Schröder, T. Weiss
Further Information

Publication History

eingereicht: 11.6.2002

akzeptiert: 19.6.2002

Publication Date:
06 August 2002 (online)

Also available at
    Permissions and Reprints

Heparin ist eine wasserlösliche polyanionische Substanz, die vor allem in Mastzellen, aber auch in basophilen Granulozyten gespeichert wird. Lunge, Leber und Darm sind besonders reichhaltig an Mastzellen und daher an Heparin.

Niedermolekulare Heparine sind ein Produkt des nativen Heparins, das, wie zahlreiche Studien der letzten Jahre gezeigt haben, natives Heparin in vielen Indikationen zumindest gleichwertig ersetzen kann. Durch die unkomplizierte Anwendung hat es auch für die ambulante Betreuung zunehmende Bedeutung erlangt.

Literatur

  • 1 Weitz J I. Low-molecular-weight heparins.  NEJM. 1997;  337 688-698
    Google Scholar
  • 2 Hirsh J, Anand S S, Halperin J L, Fuster V. Guide to anticoagulant therapy: Heparin.  Circulation. 2001;  103 2994-3018
    Google Scholar
  • 3 De Swart C A, Nijmeyer B, Roelofs J M, Sixma J J. Kinetics of intravenously administered heparin in normal humans.  Blood. 1982;  60 1251-1258
    Google Scholar
  • 4 Glimelius B, Busch C, Hook M. Binding of heparin on the surface of cultured human endothelial cells.  Thromb Res. 1978;  12 773-782
    Google Scholar
  • 5 Mahadoo J, Heibert L, Jaques L B. Vascular sequestration of heparin in man.  Thromb Res. 1978;  12 79-90
    Google Scholar
  • 6 Frydman A M, Bara L, Le Roux Y, Woler M, Chauliac F, Samana M M. The antithrombotic activity and pharmocokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 up to 80 mg.  J Clin Pharmacol. 1988;  28 609-618
    Google Scholar
  • 7 Bradbrook I D, Magnani H N, Moelker H C. et al . ORG 10 172: a low molecular weight heparinoid anticoagulant with a long half-life in man.  Br J Clin Pharmacol. 1987;  23 667-675
    Google Scholar
  • 8 Bergqvist D, Benoni G, Björgell O, Fredin H, Hedlundh U, Nicolas S, Nilsson P, Nylander G. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement.  NEJM. 1996;  335 696-700
    Google Scholar
  • 9 Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D’Angelo A, Beltrametti C, Damiani M, Andrioli G C, Pugliese R, Iorio A, Brambilla G. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery.  NEJM. 1998;  339 80-85
    Google Scholar
  • 10 Geerts W H, Jay R M, Code K I, Chen E, Szalai J P, Saibil E A, Hamilton P A. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma.  NEJM. 1996;  335 701-707
    Google Scholar
  • 11 Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie A G, Demers C, Kovacs M, Geerts W, Kassis J, Desjardins L, Cusson J, Cruickshank M, Powers P, Brien W, Haley S, Willan A. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.  NEJM. 1996;  334 677-681
    Google Scholar
  • 12 Koopman M MW, Prandoni P, Piovella F, Ockelford P A, Brandjes D PM, van der Meer J, Gallus A S, Simonneau G, Chesterman C H, Prins M H, Bossuyt P MM, De Haes H, van den Belt A GM, Sagnard L, D’Azemar P, Büller H R. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home.  NEJM. 1996;  334 682-687
    Google Scholar
  • 13 Breddin H K, Hach-Wunderle V, Nakov R, Kakkar V V. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.  NEJM. 2001;  344 626-631
    Google Scholar
  • 14 Simonneau G, Sors H, Charbonnier B, Page Y, Laaban J -P, Azarian R, Laurent M, Hirsch J -L, Ferrari E, Bosson J -L, Mottier D, Beau B. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism.  NEJM. 1997;  337 663-669
    Google Scholar
  • 15 Wallentin L, Ohlsson J, Swahn E. Low-molecular-weight heparin during instability in coronary artery disease.  Lancet. 1996;  347 561-568
    Google Scholar
  • 16 Klein W, Buchwald A, Hillis S E, Monrad S, Sanz G, Turpie A GG, van der Meer J, Olaisson E, Undeland S, Ludwig K. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease.  Circulation. 1997;  96 61-68
    Google Scholar
  • 17 Cohen M, Demers C, Gurfinkel E P, Turpie A GG, Fromell G J, Goodman S, Langer A, Califf R M, Fox K AA, Premmereur J, Bigonzi F. A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease.  NEJM. 1997;  337 447-452
    Google Scholar
  • 18 Antmann E M, McCabe C H, Gurfinkel E P, Turpie A GG, Bernink P JLM, Salein D, de Luna A B, Fox K, Lablanche J -M, Radley D, Premmereur J, Braunwald E. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.  Circulation. 1999;  100 1593-1601
    Google Scholar
  • 19 Yusuf S. for the Direct Thrombin Inhibitor Trialists’ Collaborative Group . Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients’ data.  Lancet. 2002;  359 294-302
    Google Scholar
  • 20 Montalescot G, Polle V, Collet J P, Leprince P, Bellanger A, Gandjbakhch I, Thomas D. Low molecular weight heparin after mechanical heart valve replacement.  Circulation. 2000;  101 1083-1086
    Google Scholar
  • 21 Kay R, Wong K S, Vu Y L, Chan Y W, Tsoi T H, Ahuja A T, Chan F L, Fong K Y, Law C B, Wong A, Woo J. Low-molecular-weight heparin for the treatment of acute ischemic stroke.  NEJM. 1995;  333 1588-1593
    Google Scholar
  • 22 Brott T, Bogousslavsky J. Treatment of acute ischemic stroke.  NEJM. 2000;  343 710-722
    Google Scholar
  • 23 Dimitrakakis C, Papageorgiou P, Papageorgiou I, Antzaklis A, Sakarelou N, Michalas S. Absence of transplacental passage of the low molecular weight heparin enoxaparin.  Haemostasis. 2000;  30 243-248
    Google Scholar
  • 24 Sanson B J, Lensing A W, Prins M H, Ginsberg J S, Barkagan Z S, Lavenne-Pardonge E, Brenner B, Dulitzky M, Nielsen J D, Boda Z, Turi S, Mac-Gillavry M R, Hamulyak K, Theunissen I M, Hunt B J, Buller H R. Safety of low-molecular-weight heparin in pregnancy: a systematic review.  hromb Haemost. 1999;  81 668-672
    Google Scholar
  • 25 Malsch R, Harenberg J, Guerrini M, Torri G, Casu B, Heene D L. Semisynthesis and analysis of lipophilically modified unfractionated and low molecular mass heparins.  Semin Thromb Hemost. 1994;  20 182-192
    Google Scholar
  • 26 Warkentin T E, Levine M N, Hirsh J, Horsewood P, Roberts R S, Gent M, Kelton J G. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.  N Engl J Med. 1995;  332 1330-1335
    Google Scholar
  • 27 Muir J M, Hirsh J, Weitz J I, Andrew M, Young E, Shaughnessy S G. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats.  Blood. 1997;  89 3236-3242
    Google Scholar
  • 28 Bhandari M, Hirsh J, Weitz J I, Young E, Venner T J, Shaughnessy S G. The effects of standard and low molecular weight heparin on bone nodule formation in vitro.  Thromb Haemost. 1998;  80 413-417
    Google Scholar
  • 29 Smith B S, Gandhi P J. Pharmacokinetics and phamacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure.  J Thrombosis Thrombolysis. 2001;  11 39-48
    Google Scholar
  • 30 Turpie A GG, Gallus A S, Hoek J A. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.  NEJM. 2001;  344 619-625
    Google Scholar
  • 31 Eriksson B I, Bauer K A, Lassen M R, Turpie A GG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.  NEJM. 2001;  345 1298-1304
    Google Scholar
  • 32 Bauer K A, Eriksson B I, Lassen M R, Turpie A GG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.  NEJM. 2001;  345 1305-1310
    Google Scholar

Autoren

Dr. F. Schröder,
Dr. T. Weiss

Abteilung für Kardiologie und Angiologie, Medizinischen Hochschule Hannover

Carl-Neuberg-Straße 1

30625 Hannover

      >